ClinicalTrials.Veeva

Menu
M

Metabolic Research Institute, Inc. | West Palm Beach, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Insulin icodec
AC2993
Metformin
Glucose
Sugar
Bococizumab
Ruxolitinib
Finerenone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 100 total trials

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2)

The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or o...

Active, not recruiting
Overweight
Type 1 Diabetes
Drug: Placebo
Drug: Tirzepatide

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investi...

Active, not recruiting
Diabetes Mellitus, Type 1
Drug: Insulin glargine
Drug: Insulin icodec

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high d...

Enrolling
Metabolic Dysfunction-associated Steatohepatitis
Drug: Placebo
Drug: ECC4703

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The...

Active, not recruiting
Obesity
Drug: Retatrutide
Drug: Placebo

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabet...

Enrolling
Type 1 Diabetes Mellitus With Hypoglycemia
Drug: Placebo
Drug: ZT-01, 22 mg

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Active, not recruiting
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes...

Enrolling
Type 2 Diabetes
Drug: Survodutide
Drug: Placebo

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

Active, not recruiting
Diabetes Mellitus, Type 1
Drug: Cadisegliatin 800 mg QD
Drug: Placebo

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: ADX-914

A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults wit...

Enrolling
Type 2 Diabetes Mellitus
Device: Device: Omnipod M System with study CGM
Device: Standard Therapy plus study CGM

Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open lab...

Active, not recruiting
Weight Change Trajectory
Obesity
Device: Sham
Device: Revita Duodenal Mucosal Resurfacing (DMR)

The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disp...

Active, not recruiting
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Device: MiniMed™ NMX8-AID System with DS5™/Simplera Sync™

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have ty...

Not yet enrolling
Diabetes Mellitus, Type 2
Drug: CagriSema

Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to...

Enrolling
Overweight
Obesity
Drug: ABBV-295
Drug: Placebo

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney d...

Enrolling
Diabetic Kidney Disease (DKD)
Drug: Evinacumab
Drug: ALN-ANG3

Trial sponsors

Lilly logo
Novo Nordisk logo
AstraZeneca logo
Pfizer logo
Incyte logo
Bayer logo
Boehringer Ingelheim logo
G
Abbott logo
Bausch Health logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems